FDA Approves Gemtesa for Overactive Bladder in Men With BPH
THURSDAY, Jan. 2, 2025 -- Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive bladder (OAB) symptoms receiving pharmacologic therapy for benign prostatic hyperplasia (BPH), according to a press release published by Sumitomo Pharma.
Gemtesa, a β3 adrenergic receptor agonist, dosed once daily (75 mg), has been approved for men with OAB symptoms, including urinary incontinence, urgency, and urinary frequency, who are receiving pharmacologic treatment for BPH.
The approval was based on results from a 24-week phase 3 study of Gemtesa versus placebo in about 1,100 men with OAB symptoms receiving pharmacologic therapy for BPH. All coprimary end points at week 12 were met, with significant reductions from baseline seen in the average number of micturition episodes per day and in the average number of daily urgency episodes with Gemtesa versus placebo. In addition, at 12 weeks, there was a reduction in instances of urge urinary incontinence episodes per day. Adverse reactions of hypertension and urinary tract infection exceeding the placebo rate occurred in ≥2 percent of patients treated with Gemtesa.
"The FDA's expanded approval of Gemtesa is an important milestone for the men with unresolved symptoms of OAB while being treated for BPH, which underscores our urgency to deliver for those affected by conditions with unmet need," Tsutomu Nakagawa, Ph.D., president and chief executive officer of Sumitomo Pharma America Inc., said in a statement.
Approval of Gemtesa was granted to Sumitomo Pharma.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Read this next
Surgical Volume Increases With Introduction of HoLEP
FRIDAY, Sept. 19, 2025 -- Introducing holmium laser enucleation of the prostate (HoLEP) for benign prostatic hyperplasia increases surgical volume in urology practices, according...
Magnesium Depletion Linked to Increased Overactive Bladder Risk
THURSDAY, Sept. 18, 2025 -- Magnesium depletion is associated with an increased risk for overactive bladder (OAB), according to a study published online Sept. 1 in Scientific...
MedDiet Adherence Seems Beneficial for Benign Prostatic Hyperplasia
THURSDAY, Aug. 14, 2025 -- In patients with benign prostatic hyperplasia (BPH), adherence to the Mediterranean diet (MedDiet) is associated with improved urinary function and...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.